Bibliometric Analysis of Tacrolimus in the Treatment of Myasthenia Gravis
FANG Shu-shu1,2, CHEN Di2, CHEN Qian1,2, CAO Guo-ying2*
1. Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; 2. National Center for Geriatrics of the Department of Pharmacy of Beijing Hospital, Evaluation of Clinical Risk and Individualized Application of Drugs, Beijing Key Laboratory, Beijing 100730, China
Abstract��OBJECTIVE To analyze the research on tacrolimus (FK-506) in the treatment of myasthenia gravis and provide support on clinical treatment. METHODS Databases including PubMed, Embase, Cochrane, Web of Science, CNKI, Wan Fang, VIP database were searched with time ranging from inception of databases to November 30, 2017. Endnote X7 was used to make statistical analysis of the publishing year, journal names, authors and research institutions, literature types, research contents and cited frequency. RESULTS A total of 184 articles from 18 countries were included. Types of literature: (100 articles, 54%) case discussions (41 articles, 22.2%), reviews (43 articles, 23.2%). First articles were published in 1990. Researches were mainly conducted in Japan. The most frequency was 61. Tacrolimus is a second-line treatment for the long-term treatment of myasthenia gravis. It is suitable for patients with poor response or intolerance to conventional immune preparations. CONCLUSION Japan plays an important role in tacrolimus research. Tacrolimus has low oral bioavailability, large individual differences, and many drug interactions. Myasthenia gravis treatment should be based on therapeutic drug monitoring to reduce adverse reactions.
������,���E,����,�ܹ�ӱ. ����Ī˾������֢������������������[J]. �й�ҩѧ��־, 2019, 54(3): 234-239.
FANG Shu-shu, CHEN Di, CHEN Qian, CAO Guo-ying. Bibliometric Analysis of Tacrolimus in the Treatment of Myasthenia Gravis. Chinese Pharmaceutical Journal, 2019, 54(3): 234-239.
China guidelines for the diagnosis and treatment of myasthenia gravis. Chin J Neurol (�л�����־), 2015, 48(11):934-940.
[2]
BU B. Mononuclear cell subsets in the peripheral blood of patients with myasthenia gravis. Chin J Neurol Psychiatry(�л��������־),1990, 23(3): 140-142, 188-189.
[3]
ZHAO C B, ZHU W H, LU J H. The preliminary clinical study of low-dose tacrolimus in the treatment of refractory generalized myasthenia gravis . Chin J Clin Neurosci(�й��ٴ���ѧ), 2005, 13 (4):406-409.
[4]
YOSHIKAWA H, IWASA K, SATOH K, et al. FK506 prevents induction of rat experimental autoimmune myasthenia gravis. J Autoimmun, 1997,10(1): 11-16.
[5]
OETTING W S, WU B, SCHLADT D P, et al. Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients. Pharmacogenomics J, 2017, 18(5):501-505.
[6]
CRUZ L, WOLFF M L, VANDERMAN A J, et al. The emerging role of tacrolimus in myasthenia gravis. The Adv Neurol Disord, 2015,8(2): 92-103.
[7]
SIKMA M A, MAARSEVEEN E M V, GRAAF E A, et al. Pharmacokinetics and toxicity of tacrolimus early after heart and lung transplantation. Am J Transplant, 2015, 15(9): 2301-2313.
[8]
UTSUGISAWA K, NAGANE Y. Therapeutic strategies against myasthenia gravis. Nihon Rinsho, 2013,71(5): 881-886.
[9]
PONSETI J M, GAMEZ J, AZEM J, et al. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann N Y Acad Sci, 2008, 1132(1): 254-263.
[10]
PONSETI J M, AZEM J, FORT J M, et al. Long-term results of tacrolimus in cyclosporine-and prednisone-dependent myasthenia gravis. Neurology, 2005,64(9):1641-1643.
[11]
NAGANE Y, UTSUGISAWA K, OBARA D R, et al. Efficacy of low-dose FK506 in the treatment of myasthenia gravis--a randomized pilot study. Eur Neurol, 2005,53(3):146-150.
[12]
LIU C, GUI M, CAO Y, et al. Tacrolimus improves symptoms of children with myasthenia gravis refractory to prednisone. Pediatr Neurol, 2017, 77: 42-47.
[13]
GOTTERER L, LI Y. Maintenance immunosuppression in myasthenia gravis. J Neurol Sci, 2016, 369 (10):294-302.
[14]
KONISHI T, YOSHIYAMA Y, TAKAMORI M, et al. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J Neurol Neurosurg Psychiatry, 2005, 76(3): 448-450.
[15]
PONSETI J M, GAMEZ J, AZEM J, et al. Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: a non-randomized, non-controlled study. Curr Med Res Opin, 2007, 23(6):1269-1278.
[16]
ZHAO C B, ZHANG X, ZHANG H, et al. Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis. Int Immunopharmacol, 2011, 11(4): 519-524.
[17]
BEKERSKY I, DRESSLER D, MEKKI Q A. Effect of low-and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol, 2001,41(2): 176-182.
[18]
SPITMAN A B, MOES D J A R, GELDERBLOM H, et al. Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism. Eur J Clin Pharmacol, 2017,73(12): 1589-1598.
[19]
STAATZ C E, GOODMAN L K, TETT S E. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part ��. Clin Pharmacokinet, 2010, 49(3): 141-175.
[20]
WANG D, SADEE W. CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing. Pharmacogenet Genomics, 2016,26(1): 40-43.
[21]
CHEN D,HOU S F,ZHAO M, et al. Analysis of tacrolimus therapeutic drug monitoring and influence factor in myasthenia gravis patients. Chin Pharm J(�й�ҩѧ��־),2018,53(4): 295-299.
[22]
WU X, WHITFIELD L R, STEWART B H. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res, 2000, 17(2): 209-215.
[23]
AHN S W, JOO I S, KIM B J, et al. A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis. J Neurol Sci, 2017, 379: 271-275.
[24]
THOLKING G, GERTH H U, SCHUETTE-NUETGEN K, et al. Influence of tacrolimus metabolism rate on renal function after solid organ transplantation. World J Transplant, 2017,7(1): 26-33.
2019, Vol. 54 
